Hypha Discovery is a UK-based biotechnology company that supports pharmaceutical and agrochemical companies by producing metabolites and new derivatives of drugs and pesticides in discovery and development. Hypha is an expert in the scalable synthesis of drug metabolites and oxidised derivatives of lead compounds, and possess a wealth of experience in the production, purification and structure elucidation of natural products.
NEW PolyCYPs® biocatalysis kits
Hypha’s PolyCYPs® kits provide a fast and scalable way to access CYP-derived drug metabolites and derivatives formed by oxidation at aliphatic or aromatic moieties. Download a pdf of the PolyCYPs brochure.
Click here to find out more about PolyCYPs kits
NEWS & EVENTS
Come and meet us at the following events
Organic Chemistry in the Pharmaceutical, Agrochemical and Contract Manufacturing Industries
11th – 15th November 2019, University of Copenhagen, Denmark
Our Head of Synthetic Chemistry, Lisbet Kvaerno is organising this conference at the University of Copenhagen on organic chemistry in the pharmaceutical, agrochemical and contract manufacturing industries
SCI/RSC Applied Late-stage Functionalisation: Where Chemistry meets Biology
18th – 19th February 2020, Manchester, UK
Hypha will be giving a talk on LSF using PolyCYPs enzymes
Download a copy of our brochure on drug metabolites and C-H activated derivatives
Our brochure on drug metabolites and C-H activated derivatives is now available. Inside we feature interesting case studies and client projects, including the following topics:
- Phase l CYP and non-CYP metabolites
- Phase ll conjugated metabolites such as glucuronides and sulfates
- Isotopically labelled metabolites
- Lead diversification / late stage functionalization
- Production of polar derivatives of drug lead compounds
Let us know if you would like a copy of a new paper published in Xenobiotica entitled Microbial Biotransformation – An Important Tool for the Study of Drug Metabolism, which describes some interesting projects Hypha have undertaken for Merck and Janssen with several difficult-to-synthesise hydroxylated and glucuronidated metabolites. Read the abstract at http://bit.ly/2xb6H9d
In a recent newsletter we look at the use of microbial biotransformation to produce scalable quantities of glucuronides, focussing on the synthesis of acyl glucuronides of carboxylic acid-containing drugs.
Access a pdf of the newsletter on glucuronides of carboxylic acid-containing drugs